AbbVie’s ABBV stock has risen 11.5% in the past month, mainly due to its beat-and-raise performance in the second quarter.

Earnings results often indicate what direction a company will take in the months ahead. With Q2 behind us, let’s have a look ...

AbbVie has performed better than the market over the past decade. The company has lost a major product, but its lineup and ...

AbbVie and Genmab’s epcoritamab has shown promise as part of a combination treatment for relapsed or refractory follicular ...

AbbVie (NYSE: ABBV) announced today that it has completed its acquisition of Capstan Therapeutics. With the completion of the acquisition, Capstan is now a part of AbbVie.

Construction on the site will begin in the fall and is expected to be finished by 2027. North Chicago is already home to ...

The expansion is part of AbbVie’s larger $10 billion commitment to U.S. investment in the face of Trump’s tariff threats.

AbbVie is investing $195m to strengthen domestic API production, with the expansion of its manufacturing plant in North ...

AbbVie has announced a USD 195 million investment in its North Chicago, Illinois manufacturing plant to expand domestic ...

The project aims to enhance AbbVie’s chemical synthesis capacity to support next-generation neuroscience, immunology, and ...

AbbVie (NYSE:ABBV) invests $195M in North Chicago for API production, boosting U.S. pharmaceutical manufacturing. Read more ...

The company’s commitment to its North Chicago, Ill. plant is part of a previously announced $10 billion capital investment ...